US Patent 10421744 Heteroaromatic compounds and their use as dopamine D1 ligands
Patent 10421744 was granted and assigned to Pfizer Limited on September, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 24 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+79 characters)
Article
Patent abstract
The present invention provides, in part, compounds of Formula I:
Edits on 2 Oct, 2023
Golden AI
Edits made to:
Infobox (+12 properties)
Infobox
Patent Inventor Names
Amy Beth Dounay0
Bruce Nelsen Rogers0
Chewah Lee0
David Lawrence Firman Gray0
Ivan Viktorovich Efremov0
Jaclyn Louise Henderson0
Jennifer Elizabeth Davoren0
Lei Zhang0
Michael Aaron Brodney0
Michael Eric Green0
Scot Richard Mente0
Steven Victor O'Neil0
Edits on 26 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 24 Apr, 2023
Golden AI
Infobox
Edits on 4 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 28 Sep, 2022
Golden AI
Infobox
Edits on 24 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 12 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 29 Jan, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
US Patent 10421744 Heteroaromatic compounds and their use as dopamine D1 ligands
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10421744
Date of patent
September 24, 2019
Patent application number
16123072
Date Filed
September 6, 2018
Patent primary examiner
Find more entities like US Patent 10421744 Heteroaromatic compounds and their use as dopamine D1 ligands
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
